文献速递基础与转化研究新药、器械与细胞基因治疗研发

定量免疫肽组学揭示肿瘤基质特异性T细胞治疗靶点

Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.
PubMed 文献 · Sci Transl Med · 2022-08-31

研究采用定量质谱的群体规模免疫肽组学,分析约1500份肿瘤与正常组织样本,发现胶原VI型α-3(COL6A3)基因内一个HLA-A*02:01限制性泛癌表位,因肿瘤特异性可变剪接而高呈递于多种实体瘤基质。表达天然COL6A3特异性TCR的T细胞活性有限,经亲和力增强的TCR转导T细胞可在体内特异性清除表达与原发性肿瘤标本相似拷贝数pHLA的肿瘤,且未检测到脱靶反应性。

要点

  • 约1500份肿瘤与正常组织样本的定量免疫肽组学发现COL6A3基因内HLA-A*02:01限制性泛癌表位高呈递于肿瘤基质。
  • 该表位源于肿瘤特异性可变剪接事件,在肿瘤微环境外罕见发生。
  • 天然COL6A3特异性TCR活性有限,亲和力增强TCR转导T细胞可在体内特异性清除肿瘤且未检测到脱靶反应性。

核心结论

  • 亲和力增强的COL6A3特异性TCR变体具有有利的安全性特征且未检测到脱靶反应性,为启动针对多种实体瘤的临床试验铺平道路。

研究设计与样本

  • 采用定量质谱的群体规模免疫肽组学,分析约1500份肿瘤与正常组织样本,以发现可经TCR为基础过继性T细胞治疗靶向的共享肿瘤抗原。

主要发现

  • 在胶原VI型α-3(COL6A3)基因内鉴定出一个HLA-A*02:01限制性泛癌表位,因肿瘤特异性可变剪接事件而在多种实体瘤基质中高呈递。
  • 表达天然COL6A3特异性TCR的T细胞对呈递高拷贝数COL6A3 pHLA的细胞仅表现出有限的活性。
  • 其中一个TCR经亲和力增强后,转导的T细胞可在体内特异性清除表达与原发性肿瘤标本相似拷贝数pHLA的肿瘤。
  • 增强的TCR变体表现出有利的安全性特征,未检测到脱靶反应性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T cell receptor (TCR)-based immunotherapy has emerged as a promising therapeutic approach for the treatment of patients with solid cancers. Identifying peptide-human leukocyte antigen (pHLA) complexes highly presented on tumors and rarely expressed on healthy tissue in combination with high-affinity TCRs that when introduced into T cells can redirect T cells to eliminate tumor but not healthy tissue is a key requirement for safe and efficacious TCR-based therapies. To discover promising shared tumor antigens that could be targeted via TCR-based adoptive T cell therapy, we employed population-scale immunopeptidomics using quantitative mass spectrometry across ~1500 tumor and normal tissue samples. We identified an HLA-A*02:01-restricted pan-cancer epitope within the collagen type VI α-3 (COL6A3) gene that is highly presented on tumor stroma across multiple solid cancers due to a tumor-specific alternative splicing event that rarely occurs outside the tumor microenvironment. T cells expressing natural COL6A3-specific TCRs demonstrated only modest activity against cells presenting high copy numbers of COL6A3 pHLAs. One of these TCRs was affinity-enhanced, enabling transduced T cells to specifically eliminate tumors in vivo that expressed similar copy numbers of pHLAs as primary tumor specimens. The enhanced TCR variants exhibited a favorable safety profile with no detectable off-target reactivity, paving the way to initiate clinical trials using COL6A3-specific TCRs to target an array of solid tumors.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Kim GB, Fritsche J, Bunk S, et al. Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy. Sci Transl Med. 2022. PMID: 36044599. doi:10.1126/scitranslmed.abo6135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。